|
WO2021070150A1
|
|
An inhalable dry powder composition for pulmonary diseases
|
|
WO2020148638A1
|
|
Nebulization composition comprising glycopyrrolate and arformoterol
|
|
WO2020141482A1
|
|
Pharmaceutical compositions comprising mupirocin
|
|
US2020215051A1
|
|
Nebulization composition comprising tiotropium and indacaterol
|
|
WO2020105012A1
|
|
Sterile compositions of indacaterol suitable for nebulization
|
|
WO2020100096A1
|
|
Topical composition comprising mupirocin
|
|
WO2020084549A1
|
|
Nebulization composition comprising glycopyrrolate and formoterol
|
|
EP3808777A1
|
|
Stable liquid antibody formulations
|
|
WO2020070599A1
|
|
Nebulization composition of mometasone
|
|
US2019282551A1
|
|
Tiotropium inhalation solution for nebulization
|
|
WO2019162902A1
|
|
Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
|
|
TW201927359A
|
|
Dispensing device and pharmaceutical composition for the treatment of rhinitis
|
|
KR20200023599A
|
|
Pharmaceutical compositions and dispensing devices for the treatment of rhinitis
|
|
US2019030047A1
|
|
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
|
|
US2018369187A1
|
|
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
|
|
KR20190085926A
|
|
Sprayed thiotropium
|
|
EP3525773A1
|
|
Nebulizable compositions of tiotropium and formoterol
|
|
US2017326117A1
|
|
Tiotropium inhalation solution for nebulization
|
|
US2017333449A1
|
|
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
|
|
US2017189422A1
|
|
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
|
